The RECOVER-NEURO trial is intended to look at accessible interventions for cognitive dysfunction associated with Covid, such as brain fog, memory issues, and difficulty in paying attention, among others
The REMOTE-tDCS platform. (Credit: PR Newswire/Soterix Medical, Inc.)
Soterix Medical, a provider of brain stimulation technology, has launched the Phase 2 RECOVER-NEURO clinical trial of the combination of the REMOTE-tDCS platform and a brain training programme for the treatment of long Covid.
The trial will be carried out via the home-based remotely supervised (RS) tDCS programme of NYU Langone Health. The programme includes a clinical service for patients all over the US.
The Researching Covid to Enhance Recovery (RECOVER) Initiative, led by the National Institutes of Health (NIH), was established to address the numerous and varied effects of long Covid.
Soterix Medical chief product officer Kamran Nazim said: “Soterix Medical tDCS-LTE platforms have been shown in prior studies to improve cognition in healthy adults, and have shown promise in a variety of clinical conditions, including many conditions associated with cognitive or attention impairment or brain fog.
“Basic science studies have shown a dual action of tDCS-LTE deriving from both boosting brain plasticity and enhancing brain blood flow. This provides a strong rationale for testing tDCS-LTE for Long Covid.”
According to the US-based Soterix Medical, the RECOVER-NEURO trial is intended to look at accessible interventions for cognitive dysfunction associated with Covid. These include brain fog, memory issues, and difficulty in paying attention, thinking clearly, and solving problems.
The interventions under this protocol consist of the PASC-Cognitive Recovery, a web-based goal management training programme created by Mount Sinai Health System, and the digital cognitive training programme by Posit Science.
It also includes the home-based transcranial direct current stimulation (tDCS) system created by Soterix Medical for use in remotely supervised transcranial direct current stimulation (RS-tDCS). The RECOVER-NEURO trial is anticipated to evaluate up to 315 individuals.
Soterix Medical CEO Abhishek Datta said: “The Soterix Medical REMOTE-tDCS platform is the most validated hardware and software system for home-based tDCS.
“REMOTE-tDCS combines unique accessories, tDCS-LTE hardware, and telemedicine which can be customised for each clinical indication.
“NIH RECOVER-NEURO develops a Long Covid treatment based on digital therapy and Soterix Medical’s REMOTE-tDCS platform.”